BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12171569)

  • 1. The non-diaryl heterocycle classes of p38 MAP kinase inhibitors.
    Cirillo PF; Pargellis C; Regan J
    Curr Top Med Chem; 2002 Sep; 2(9):1021-35. PubMed ID: 12171569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors.
    Dumas J; Hatoum-Mokdad H; Sibley R; Riedl B; Scott WJ; Monahan MK; Lowinger TB; Brennan C; Natero R; Turner T; Johnson JS; Schoenleber R; Bhargava A; Wilhelm SM; Housley TJ; Ranges GE; Shrikhande A
    Bioorg Med Chem Lett; 2000 Sep; 10(18):2051-4. PubMed ID: 10999468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a new class of p38 kinase inhibitors.
    Dumas J; Sibley R; Riedl B; Monahan MK; Lee W; Lowinger TB; Redman AM; Johnson JS; Kingery-Wood J; Scott WJ; Smith RA; Bobko M; Schoenleber R; Ranges GE; Housley TJ; Bhargava A; Wilhelm SM; Shrikhande A
    Bioorg Med Chem Lett; 2000 Sep; 10(18):2047-50. PubMed ID: 10999467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors.
    Revesz L; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Zimmerlin AG
    Bioorg Med Chem Lett; 2000 Jun; 10(11):1261-4. PubMed ID: 10866395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.
    Pargellis C; Tong L; Churchill L; Cirillo PF; Gilmore T; Graham AG; Grob PM; Hickey ER; Moss N; Pav S; Regan J
    Nat Struct Biol; 2002 Apr; 9(4):268-72. PubMed ID: 11896401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural comparison of p38 inhibitor-protein complexes: a review of recent p38 inhibitors having unique binding interactions.
    Wrobleski ST; Doweyko AM
    Curr Top Med Chem; 2005; 5(10):1005-16. PubMed ID: 16178743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Reverse' alpha-ketoamide-based p38 MAP kinase inhibitors.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5456-9. PubMed ID: 18835164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule p38 inhibitors: novel structural features and advances from 2002-2005.
    Hynes J; Leftheri K
    Curr Top Med Chem; 2005; 5(10):967-85. PubMed ID: 16178741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor.
    Dumas J; Hatoum-Mokdad H; Sibley RN; Smith RA; Scott WJ; Khire U; Lee W; Wood J; Wolanin D; Cooley J; Bankston D; Redman AM; Schoenleber R; Caringal Y; Gunn D; Romero R; Osterhout M; Paulsen H; Housley TJ; Wilhelm SM; Pirro J; Chien DS; Ranges GE; Shrikhande A; Muzsi A; Bortolon E; Wakefield J; Gianpaolo Ostravage C; Bhargava A; Chau T
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1559-62. PubMed ID: 12039561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase.
    Fox T; Coll JT; Xie X; Ford PJ; Germann UA; Porter MD; Pazhanisamy S; Fleming MA; Galullo V; Su MS; Wilson KP
    Protein Sci; 1998 Nov; 7(11):2249-55. PubMed ID: 9827991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors.
    Ramurthy S; Aikawa M; Amiri P; Costales A; Hashash A; Jansen JM; Lin S; Ma S; Renhowe PA; Shafer CM; Subramanian S; Sung L; Verhagen J
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3286-9. PubMed ID: 21543226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein kinase inhibitors from the urea class.
    Dumas J
    Curr Opin Drug Discov Devel; 2002 Sep; 5(5):718-27. PubMed ID: 12630292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity.
    Scapin G; Patel SB; Lisnock J; Becker JW; LoGrasso PV
    Chem Biol; 2003 Aug; 10(8):705-12. PubMed ID: 12954329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Phenyl-N-purin-6-yl ureas: the design and synthesis of p38alpha MAP kinase inhibitors.
    Wan Z; Boehm JC; Bower MJ; Kassis S; Lee JC; Zhao B; Adams JL
    Bioorg Med Chem Lett; 2003 Mar; 13(6):1191-4. PubMed ID: 12643941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperosmolality induced by betaine or urea stimulates endothelin synthesis by differential activation of ERK and p38 MAP kinase in MDCK cells.
    Kramer HJ; Hashemi T; Bäcker A; Bokemeyer D
    Kidney Blood Press Res; 2002; 25(2):65-70. PubMed ID: 12077486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogue.
    Mavunkel BJ; Chakravarty S; Perumattam JJ; Luedtke GR; Liang X; Lim D; Xu YJ; Laney M; Liu DY; Schreiner GF; Lewicki JA; Dugar S
    Bioorg Med Chem Lett; 2003 Sep; 13(18):3087-90. PubMed ID: 12941340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors.
    Ramurthy S; Costales A; Jansen JM; Levine B; Renhowe PA; Shafer CM; Subramanian S
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1678-81. PubMed ID: 22264479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MAP kinase inhibitors, PD098059, UO126 and SB203580, inhibit IL-1beta-dependent PGE(2) release via mechanistically distinct processes.
    Newton R; Cambridge L; Hart LA; Stevens DA; Lindsay MA; Barnes PJ
    Br J Pharmacol; 2000 Jul; 130(6):1353-61. PubMed ID: 10903976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of MAP kinase pathways in mediating IL-6 production in human primary mesangial and proximal tubular cells.
    Leonard M; Ryan MP; Watson AJ; Schramek H; Healy E
    Kidney Int; 1999 Oct; 56(4):1366-77. PubMed ID: 10504489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and SAR of p38alpha MAP kinase inhibitors based on heterobicyclic scaffolds.
    Murali Dhar TG; Wrobleski ST; Lin S; Furch JA; Nirschl DS; Fan Y; Todderud G; Pitt S; Doweyko AM; Sack JS; Mathur A; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2007 Sep; 17(18):5019-24. PubMed ID: 17664068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.